Tiffany Khong

Tiffany Khong

UNVERIFIED PROFILE

Are you Tiffany Khong?   Register this Author

Register author
Tiffany Khong

Tiffany Khong

Publications by authors named "Tiffany Khong"

Are you Tiffany Khong?   Register this Author

18Publications

148Reads

27Profile Views

Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study).

Leuk Lymphoma 2019 Jun 11:1-9. Epub 2019 Jun 11.

a Myeloma Research Group, Australian Centre for Blood Diseases , Alfred Hospital/Monash University , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1571201DOI Listing
June 2019

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients.

Cancers (Basel) 2019 Jun 25;11(6). Epub 2019 Jun 25.

Myeloma Research Group, Australian Centre for Blood Diseases (ACBD), Clinical Central School, Monash University, Melbourne 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11060887DOI Listing
June 2019

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients.

Cancers (Basel) 2019 Jun 29;11(7). Epub 2019 Jun 29.

Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne 3004, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11070917DOI Listing
June 2019

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.

Int J Mol Sci 2018 Jun 24;19(7). Epub 2018 Jun 24.

Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital⁻Monash University, Melbourne 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19071858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073672PMC
June 2018

β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.

Mol Cancer Ther 2017 09 12;16(9):1765-1778. Epub 2017 May 12.

Myeloma Research Group, Australian Centre for Blood Diseases, Monash University/Alfred Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-16-0624DOI Listing
September 2017

A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.

Haematologica 2015 Feb 7;100(2):e60-2. Epub 2014 Nov 7.

Alfred Hospital, Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Melbourne

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.111385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803129PMC
February 2015

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Epigenetics 2014 Nov;9(11):1511-20

a Myeloma Research Group; Division of Blood Cancers; Australian Center for Blood Diseases; Alfred Hospital; Monash University ; Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/15592294.2014.983367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622977PMC
November 2014

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

Mol Cancer Ther 2011 Oct 22;10(10):1909-17. Epub 2011 Aug 22.

Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0174DOI Listing
October 2011

CYT997 causes apoptosis in human multiple myeloma.

Invest New Drugs 2011 Apr 12;29(2):232-8. Epub 2009 Nov 12.

Myeloma Research Group, Malignant Haematology and Stem Cell Transplantation, South Block, Alfred Hospital, Prahran, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9350-5DOI Listing
April 2011

Deactylase inhibition in myeloproliferative neoplasms.

Invest New Drugs 2010 Dec 3;28 Suppl 1:S50-7. Epub 2010 Dec 3.

Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital/Monash University, Commercial Road, Melbourne, Victoria, 3004, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-010-9590-4
Publisher Site
http://dx.doi.org/10.1007/s10637-010-9590-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003795PMC
December 2010

The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.

Haematologica 2008 Jun 28;93(6):860-9. Epub 2008 Apr 28.

Myeloma Research Group, Department of Clinical Haematology and Bone Marrow Transplantation, Alfred Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.12261DOI Listing
June 2008

PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.

Blood 2007 Feb 10;109(4):1712-9. Epub 2006 Oct 10.

Myeloma Research Group, The Alfred Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-05-014092DOI Listing
February 2007

A study of VEGF and its receptors in two rat models of proteinuria.

Nephron Physiol 2004 ;96(1):P26-36

Department of Nephrology, University of Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000075577DOI Listing
May 2004